Patients Are Reaping the Benefits of Switching From Pharmaceuticals to MMJ
by Chane Leigh
Researchers working at the University of Arizona College of Medicine in Tucson have refined a method of ketamine use in the treatment of Parkinson’s disease (PD). Specifically, the group focused on ketamine’s ability to relieve the side effects of a common treatment called Levodopa.
Nicknamed “K,” “special K,” “cat valium,” and “vitamin K,” ketamine is also commonly referred to as “horse tranquilizer.” While it is approved for use as a sedative for animals, it is also utilized as an anesthetic for people. Once known solely as a party drug, ketamine is starting to earn a new reputation thanks to research efforts into its potentially medicinal qualities.
Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc., a subsidiary of Newscope Capital Corporation, for the development and marketing of their unique treatment.
The University of Arizona’s researchers learned that the unwanted side effects of Levodopa, a commonly used method of treatment for PD, could be drastically reduced with ketamine. According to the team, administration of ketamine had a noticeably diminishing effect on involuntary limb movements, aka “dyskinesia.”
Titled, “KET-LID study,” the study into the safety, efficacy, and tolerability of low-dose ketamine infusion for Levodopa consumers is not brand new—it was carried out around five years ago. However, it is attracting fresh attention amid the rise of psychedelics in medicine.
Not only did researchers discover that dyskinesia symptoms noticeably shrank in patients who received ketamine treatment, but they also learned that ketamine-treated patients experienced no serious negative side effects. Researchers were prepared for the adverse effects that were reported, all of which were either mild or moderate.
The study’s findings prompted another study, but this time into rodents with PD. As the team predicted, ketamine did stop uncontrollable movements for a total of three days before returning 10 days post-consumption as baseline involuntary movement.
Based on preclinical data results and five case studies in PD patients, University of Arizona associate professors Scott Sherman, MD, Ph.D., and Torsten Falk, Ph.D., collaborated with Tech Launch Arizona—the university’s technology commercialization office—to submit a patent application.
Dr. Sherman, the study’s lead investigator, says that ketamine has long been “overlooked” and, taking into account the recent study’s results, the substance may offer a number of advantages for Parkinson’s patients. “The results of this clinical study further support that ketamine is well-tolerated even in an older population of patients with advanced Parkinson’s disease,” said Sherman.
Unfortunately, no cure currently exists for PD. However, in most cases, a drug called Levodopa is used to reduce the severity of symptoms. The drug falls into a class of medications known as “nervous system agents.”
Although effective at reducing the symptoms of PD, Levodopa causes dyskinesia in 40% of patients. Dyskinesia may arise after long-term Levodopa use, and it is characterized by erratic and involuntary movements of the arms, face, legs, or trunk. Only after a Parkinson’s patient stops using Levodopa will the unwanted side effects disappear, but this means that the symptoms of PD will resurface.
Fortunately, Sherman says that the new research “opens the door to a fast-track development of a novel non-surgical treatment for levodopa-induced dyskinesia that will fill a major gap in the existing therapeutic arsenal.” His opinion is shared by the CEO of PharmaTher, Fabio Chianelli:
“It gives us further confidence that ketamine can safely and effectively reduce LID in patients with Parkinson’s disease and it paves the way for a potential Phase III clinical study.”
As many as 250 clinics across the U.S. are currently receiving legal off-label ketamine to assist them in treating depressed patients. Although the Food and Drug Administration (FDA) approved ketamine as an anesthetic in the 1970s, the FDA has not yet validated its use for mental health and pain disorders.
Notwithstanding the FDA’s stand-offish approach to ketamine-approved treatments, there’s no doubting the fact that the dissociative anesthetic harbors potential as an aid for treating anxiety, depression, Parkinson’s disease, and PTSD, to name a few. For example, a 2021 review found that intranasal ketamine may be a safe and effective alternative to intravenous opioids for adult patients who suffer from acute pain.
At the current time, researchers are busy carrying out a small-scale Phase I clinical trial into ketamine for PD. As part of the trial, UA investigators will explore the effects of ketamine on a total of 10 Parkinson’s patients to understand just how suitable ketamine could be for relieving the side effects of Levodopa-induced dyskinesia. The study’s outcome will be revealed during a medical congress presentation no later than June 2022.
The Coronavirus has been around for a few years. During this time, researchers conducted studies on a wide range of topics. A 2022 study published in the Journal of Cannabis Research explored cannabis consumption and COVID-19. Researchers found that those who consume cannabis were associated with lower COVID-19 severity among those who have been hospitalized,…
Is there anything that cannabis cannot do? As more research is conducted, the list of health benefits grows. One recent discovery indicates that the cannabinoid CBD (cannabidiol) might just be the next big thing for treating testosterone imbalances. Studies have outlined that CBD — a non-psychoactive cannabinoid, rich in anti-inflammatory and anxiolytic properties — may…
Chicken soup for the soul? Well, if it’s infused with cannabis, it’s going to do more than soothe the soul! Whether you consider yourself a talented cook or someone who merely enjoys dabbling with different dishes in the kitchen, this cannabis-infused chicken soup recipe will have you yearning for another spoonful after each gulp. But…
A Black-owned farm in Florida received a cannabis license for the first time, German officials are looking to California for cannabis industry inspo, and Sen. Booker made a case for federal legalization. Let’s dive into this week’s cannanews. Gwinn Brothers Beat Florida’s Rigid Application Process After years of delays, Florida finally awarded its first Black…
Everyone knows that alcohol, tobacco, and cannabis are three of the most commonly used substances in the world. While it is nearly impossible to measure the exact extent to which those substances are consumed, a recent study interestingly found that more Americans are now smoking cannabis than tobacco. Considering all the controversy surrounding cannabis, it…
Question: I live in a state with legal cannabis and started shopping at my local dispensary a few times a month. I’m grateful…
Question: I’m a teacher, and I start another year of teaching next week and really need your help! Over the summer I was…